AbbVie Launches Strategic Collaboration with HotSpot
Therapeutics to Further Expand Immunology Pipeline
AbbVie (NYSE: ABBV) and
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and
development of small molecule allosteric therapies for the treatment of cancer and autoimmune
diseases, today announced an exclusive worldwide collaboration and option to license
agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune
Carrick Therapeutics Announces $35 Million Investment from Pfizer
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a $35 million investment from Pfizer to support its rapid development of samuraciclib (CT-7001) in HR+, HER2- breast cancer, which represents more than two thirds of all new female breast cancer cases.1
Revelation Partners Expands Team and Appoints New Partners Fred Lee and Liz Staley
Revelation Partners, a healthcare investment firm with over $900 million of capital under management, announced today that it is expanding its leadership team with the appointment of Fred Lee and Chief Compliance Officer Liz Staley as Partners of the firm. Revelation Partners provides liquidity and flexible capital solutions to investors, companies, limited partners and general partners across all healthcare sub-sectors, including medical devices, diagnostics, biotech, health-tech, and healthcare services.
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. (“Akili”), is expected to start trading on The Nasdaq Capital Market (“Nasdaq”) under the new ticker symbol “AKLI” on August 22, 2022.
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
Syapse, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced the closing of a $35 million growth funding transaction to expand Syapse’s focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus), with participation from existing investors including Ally Bridge Group, Amgen Ventures, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform
Dren Bio, Inc.today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years. “We are truly grateful for all the support we continue to receive from such an outstanding syndicate of investors,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio.
Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of its Series B funding round of $147.5 million. GV, LYFE Capital and Revelation Partners co-led the investment round with participation from additional new investors Newton Investment Management, Singapore-based global investor EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment and others.
IntelyCare Secures $115 Million Series C Financing Led by Janus Henderson Investors
IntelyCare, the leading tech-enabled nurse staffing platform for healthcare organizations in the United States, today announced it has secured $115 million in a Series C financing round led by Janus Henderson Investors, a leading global investment firm and asset manager. The funding, valuing IntelyCare at $1.1 billion, also includes investments by prominent new and existing investors, including Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures.
Gravie Secures $75 Million in Financing Led by Georgian
Gravie, a leading health benefits company, announced today that it has raised $75 million in a Series E round of financing led by Georgian, a growth-stage investor based in Canada, with participation from existing investors FirstMark Capital, AXA Venture Partners, Split Rock Partners and Revelation Partners. The capital will be used to fuel Gravie's continued growth through investments in all areas of the company including product and technology, sales and marketing, and expansion into new markets through new and existing distribution channels.
Omada Health Closes $192 Million Series E Financing to Bring Virtual-First Care to Millions
Omada Health, a chronic care integrated healthcare provider, announced its $192 million Series E funding round led by Fidelity Management & Research Company with participation from aMoon, existing investors Perceptive Advisors, Wellington Management, Civilization Ventures, and others.
Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors. Also participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi and existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures.
Endeavor BioMedicines Closes $101M Series B Financing To Advance Clinical-Stage Precision Medicine Pipeline
Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Akili Interactive (“Akili” or the “Company”), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), a special purpose acquisition company.
Immunocore Announces FDA Approval of KIMMTRAK® (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases today announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
Digital Health Leader Verana Health Secures $150M Series E Funding Round
Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, today announced a $150 million Series E funding round led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings.
Vista Equity Invests $300 Million in Telehealth Software Firm TigerConnect Sources
Healthcare communications software provider TigerConnect has raised $300 million in growth investment from private equity firm Vista Equity Partners, sources familiar with the matter told Reuters on Monday. The valuation of TigerConnect wasn't known. It last raised $45 million at a valuation of $370 million in September 2020, according to PitchBook data, counting HealthQuest Capital and New Leaf Ventures as its backers.